Abbokinase is the trade name for urokinase, an enzyme produced by human kidneys to lyse (dissolve) blood clots. Abbokinase is approved for the lysis of acute massive pulmonary embolism and has been commercialized for more than 20 years.
It has been distributed via three major drug wholesalers through various group purchasing organization (GPO) contracts, and is on formulary at approximately 400 hospitals across the US.
“This acquisition is complementary to the company’s existing development programs, which include recombinant urokinase and recombinant pro-urokinase, both of which have completed phase III trials,” noted Dr Evan Unger, president and CEO of ImaRx.
ImaRx is developing and commercializing innovative therapies for vascular disorders associated with blood clots based on two platforms, thrombolytics and SonoLysis, a technology combining its proprietary nanobubbles with ultrasound to treat stroke, and other vascular diseases.